Literature DB >> 16919704

A novel in vitro system to generate and study latently HIV-infected long-lived normal CD4+ T-lymphocytes.

Gautam K Sahu1, Kyeongeun Lee, Jiaxiang Ji, Vivian Braciale, Samuel Baron, Miles W Cloyd.   

Abstract

Studies of mechanisms of HIV-latency and its reactivation in long-lived resting CD4+ T-lymphocytes in patients have been limited due to the very low frequency of these cells ( approximately 1-10 cells per 10(6) CD4+ T-cells). To circumvent this obstacle, an in vitro culture system for post-activation long-term survival of normal CD4+ T-cells in a quiescent (non-cycling) state was developed and used to generate latently infected, long-lived quiescent CD4+ T-cells from HIV-infected, activated normal CD4+ T-lymphocytes. This yielded a frequency of approximately 5x10(4) latently infected cells per 10(6) cells in culture, which is approximately 10(3)- to 10(4)-fold higher than that available from patients. Moreover, 5-10% of long-term surviving non-cycling T-cells were found to make infectious HIV continuously at low levels, showing that HIV production from infected T-cells does not require full cellular activation. This model system should facilitate studies of long-lived, latently infected and persistently HIV-producing quiescent normal CD4+ T-lymphocytes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16919704     DOI: 10.1016/j.virol.2006.07.020

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  53 in total

Review 1.  Studies of HIV-1 latency in an ex vivo model that uses primary central memory T cells.

Authors:  Alberto Bosque; Vicente Planelles
Journal:  Methods       Date:  2010-10-21       Impact factor: 3.608

Review 2.  HIV reservoirs and latency models.

Authors:  Matthew J Pace; Luis Agosto; Erin H Graf; Una O'Doherty
Journal:  Virology       Date:  2011-02-01       Impact factor: 3.616

Review 3.  HIV-1 transcription and latency: an update.

Authors:  Carine Van Lint; Sophie Bouchat; Alessandro Marcello
Journal:  Retrovirology       Date:  2013-06-26       Impact factor: 4.602

4.  HIV latency can be established in proliferating and nonproliferating resting CD4+ T cells in vitro: implications for latency reversal.

Authors:  Michael A Moso; Jenny L Anderson; Samantha Adikari; Lachlan R Gray; Georges Khoury; Judy J Chang; Jonathan C Jacobson; Anne M Ellett; Wan-Jung Cheng; Suha Saleh; John J Zaunders; Damian F J Purcell; Paul U Cameron; Melissa J Churchill; Sharon R Lewin; Hao K Lu
Journal:  AIDS       Date:  2019-02-01       Impact factor: 4.177

Review 5.  Barriers for HIV Cure: The Latent Reservoir.

Authors:  Sergio Castro-Gonzalez; Marta Colomer-Lluch; Ruth Serra-Moreno
Journal:  AIDS Res Hum Retroviruses       Date:  2018-08-28       Impact factor: 2.205

6.  Myeloid Dendritic Cells Induce HIV Latency in Proliferating CD4+ T Cells.

Authors:  Nitasha A Kumar; Renee M van der Sluis; Talia Mota; Rachel Pascoe; Vanessa A Evans; Sharon R Lewin; Paul U Cameron
Journal:  J Immunol       Date:  2018-07-20       Impact factor: 5.422

7.  Primary cell model for activation-inducible human immunodeficiency virus.

Authors:  Bryan Burke; Helen J Brown; Matthew D Marsden; Gregory Bristol; Dimitrios N Vatakis; Jerome A Zack
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

8.  Single-Cell Analysis of Quiescent HIV Infection Reveals Host Transcriptional Profiles that Regulate Proviral Latency.

Authors:  Todd Bradley; Guido Ferrari; Barton F Haynes; David M Margolis; Edward P Browne
Journal:  Cell Rep       Date:  2018-10-02       Impact factor: 9.423

Review 9.  From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication.

Authors:  Liang Shan; Robert F Siliciano
Journal:  Bioessays       Date:  2013-04-24       Impact factor: 4.345

Review 10.  Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies.

Authors:  Laurence Colin; Carine Van Lint
Journal:  Retrovirology       Date:  2009-12-04       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.